Ultrasound Contrast Agent Patents (Class 424/9.5)
-
Publication number: 20100021391Abstract: The present invention is directed to novel compositions and methods utilizing nanoparticles comprising protein cages for delivery of imaging and antimicrobial agents to biofilm forming bacterial colonies.Type: ApplicationFiled: July 13, 2007Publication date: January 28, 2010Applicant: MONTANA STATE UNIVERSITYInventors: Trevor Douglas, Mark J. Young, Peter Suci
-
Publication number: 20100008855Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.Type: ApplicationFiled: May 29, 2009Publication date: January 14, 2010Applicant: IMMUNOMEDICS, INC.Inventors: David M. Goldenberg, Hans J. Hansen, William J. McBride
-
Publication number: 20100003195Abstract: The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides.Type: ApplicationFiled: June 8, 2009Publication date: January 7, 2010Inventors: Aaron K. Sato, Daniel J. Sexton, Daniel T. Dransfield, Robert C. Ladner, Christophe Arbogast, Philippe Bussat, Hong Fan, Sudha Khurana, Karen E. Linder, Edmund R. Marinelli, Palaniappa Nanjappan, Adrian D. Nunn, Radhakrishna Pillai, Sibylle Pochon, Kondareddiar Ramalingam, Ajay Shrivastava, Bo Song, Rolf E. Swenson, Mathew A. Von Wronski
-
Patent number: 7641891Abstract: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.Type: GrantFiled: October 30, 2007Date of Patent: January 5, 2010Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, David M. Goldenberg
-
Publication number: 20090318746Abstract: Medical devices can include a lubricious echogenic coating that is slippery when wet and provides visibility during ultrasonic imaging.Type: ApplicationFiled: January 31, 2007Publication date: December 24, 2009Applicant: ANGIOTECH BIOCOATINGS CORP.Inventors: Kenneth Bruce Thurmond, II, Robert Lyon Henn, Rui Avelar
-
Publication number: 20090297455Abstract: A device (100) for activating a physiologically effective substance (101) by ultrasonic waves (103, 105), the device comprising an ultrasonic transducer (102) adapted to generate ultrasonic waves (103), a focusing element (104) adapted to focus the generated ultrasonic waves (103), and an adjustment unit (107) adapted to adjust a position (106) to which the focusing element (105) focuses the generated ultrasonic waves (103) in a manner that the focused ultrasonic waves (103) are bringable in interaction with the physiologically effective substance (101) at the adjusted position (106).Type: ApplicationFiled: August 7, 2007Publication date: December 3, 2009Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.Inventors: Jan Suijver, Cornelis Reinder Ronda
-
Publication number: 20090297441Abstract: The use of silicon as an imaging agent is described.Type: ApplicationFiled: September 22, 2006Publication date: December 3, 2009Inventors: Leigh Trevor Canham, Anna Agnieszka Kluczewska, Jerome Paul Barley, Raphaela Fortes Drummond Chicarino Varajao
-
Publication number: 20090291048Abstract: The present invention provides molecules capable of specifically binding the activated form of the beta-integrin Mac-1. The molecules may be provided in the form of peptides, polypeptides and single chained antibodies. The molecules may be used therapeutically for the treatment of disease mediated by Mac-1 (such as inflammation), or used diagnostically to locate sites of Mac-1 activity in the body.Type: ApplicationFiled: October 25, 2006Publication date: November 26, 2009Applicant: Baker IDI Heart and Diabetes Institute Holdings LimitedInventors: Karlheinz Peter, Steffen Eisenhardt, Meike Schwarz
-
Publication number: 20090285760Abstract: A method of detecting an accessory cancer lesion, comprising an administration step wherein indocyanine green is administered to a living body, an irradiation step wherein a target organ suspected of having cancer is surgically exposed and irradiated with excitation light of indocyanine green, an imaging step wherein a near-infrared fluorescence intensity distribution image from the excited indocyanine green in the target organ is obtained, and an identification step wherein an area having the near-infrared fluorescence in the intensity distribution image, excluding the area detected in preoperative examination or intraoperative macroscopic observation, is identified as an accessory cancer lesion.Type: ApplicationFiled: May 14, 2009Publication date: November 19, 2009Applicants: OSAKA PREFECTURAL HOSPITAL ORGANIZATION, HAMAMATSU PHOTONICS K.K.Inventors: Osamu ISHIKAWA, Terumasa YAMADA, Kunihito GOTOH, Mitsuharu MIWA, Takahiro SHIKAYAMA
-
Publication number: 20090274628Abstract: Methods and suspensions are provided that are useful for preparing readily reconstitutable, dry compositions of micro- or nanospheres. The dry compositions find use in diagnostic applications such as ultrasonic imaging. The suspension includes as key ingredients one or both of t-butyl alcohol and/or an amorphous sugar (or mixture of amorphous sugars) in specified amounts that reduce aggregation of the particles comprising the suspension.Type: ApplicationFiled: December 5, 2008Publication date: November 5, 2009Applicant: Point Biomedical CorporationInventors: Thomas B. Ottoboni, Robert E. Short
-
Publication number: 20090269277Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Preferred embodiments concern hexameric stably tethered structures comprising one or more IgG antibody fragments and which may be monospecific or bispecific. The disclosed methods and compositions provide a facile and general way to obtain stably tethered structures of virtually any functionality and/or binding specificity. The stably tethered structures may be administered to subjects for diagnostic and/or therapeutic use, for example for treatment of cancer or autoimmune disease. The stably tethered structures may bind to and/or be conjugated to a variety of known effectors, such as drugs, enzymes, radionuclides, therapeutic agents and/or diagnostic agents.Type: ApplicationFiled: March 3, 2009Publication date: October 29, 2009Applicant: IBC PHARMACEUTICALS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Publication number: 20090263327Abstract: Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume in vivo.Type: ApplicationFiled: June 1, 2009Publication date: October 22, 2009Applicant: Mallinckrodt Inc.Inventors: Samuel Achilefu, Raghavan Rajagopalan, Richard B. Dorshow, Joseph E. Bugaj, Muthunadar P. Periasamy
-
Publication number: 20090246125Abstract: An image enhancing agent of a form comprising an effective quantity of an image enhancing material chemically or physically bound to or encapsulated within a support comprising, preferentially, an exine coating of spores of various plants or fungi, optionally with further excipients.Type: ApplicationFiled: December 14, 2005Publication date: October 1, 2009Inventors: Stephen Lawrence Atkin, Stephen Thomas Beckett, Grahame Mackenzie
-
Publication number: 20090246142Abstract: The present invention provides triggered self-assembly nanosystems. Such nanosystems comprise a population of triggered self-assembly conjugates, each conjugate comprising one or more monomeric units and one or more complementary binding moieties. In some embodiments, inventive nanosystems and conjugates can be used to treat and/or diagnose a disease, disorder, and/or condition.Type: ApplicationFiled: March 9, 2007Publication date: October 1, 2009Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Sangeeta N. Bhatia, Todd J. Harris, Geoffrey von Maltzahn
-
Publication number: 20090238756Abstract: Compositions and methods for imaging and for chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns agents comprising a targeting moeity comprising a beta-adrenergic receptor targeting compound conjugated or embedded with ethylenediamine. The present invention also concerns methods of application of such agents for imaging and treatment of cardiovascular diseases, and kits for preparing a radiolabeled therapeutic or diagnostic agent.Type: ApplicationFiled: December 19, 2008Publication date: September 24, 2009Inventors: David J. Yang, Chang-Sok Oh, Saady Kohanim, Dong-Fang Yu, Richard Mendez, E. Edmund Kim
-
Patent number: 7591996Abstract: Selective occlusion of a blood vessel is achieved by selectively damaging endothelial cells at a target location in the blood vessel, resulting in the formation of a fibrin clot proximate to the damaged endothelial cells. Additional fibrinogen can then be introduced into the blood vessel if occlusion is not achieved, as the fibrinogen is converted to fibrin by enzymes released by the exposed thrombogenic tissue and activated platelets. Endothelial cells are selectively damaged using thermal effects induced by ultrasound, by mechanical effects induced by ultrasound, or by mechanical effects produced by a tool introduced into the blood vessel (such as a catheter-based tool). A particularly preferred technique for selectively damaging endothelial cells involves introducing an ultrasound activatable agent into the blood vessel, and causing cavitation in that agent using pulses of high-intensity focused ultrasound having a duration insufficient to induce thermal damage in adjacent perivascular tissue.Type: GrantFiled: August 17, 2005Date of Patent: September 22, 2009Assignee: University of WashingtonInventors: Joo Ha Hwang, Andrew Brayman
-
Publication number: 20090232733Abstract: The present invention provides IGIV and IGIV enriched for binding to amyloid fibrils and to partially denatured amyloidogenic precursor polypeptides. The present invention also provides methods for obtaining IGIV enriched for binding to amyloid fibrils and to partially denatured amyloidogenic precursor polypeptides. The IGIV recognizes amyloid fibrils and partially denatured amyloidogenic precursor polypeptides. They are useful for treating diseases and conditions associated with amyloid deposition. The IGIV of the present invention also are useful for diagnosing and detecting amyloid deposition.Type: ApplicationFiled: April 13, 2006Publication date: September 17, 2009Inventors: Brian O'Nuallain, Rudi Hrncic, Jonathan S. Wall, Alan Solomon
-
Patent number: 7588547Abstract: An apparatus and method for treating subcutaneous tissues using acoustic waves in the range of low acoustic pressure ultrasound waves is disclosed. The method includes injections of enhancing agents, wherein disruption of subcutaneous tissues and subcutaneous cavitational bioeffects are produced by ultrasound waves having a power that will not produce tissue cavitation in the absence of the enhancing agents. The apparatus and method of use is useful for treatment of subcutaneous abnormalities including cellulite, lipomas, and tumors.Type: GrantFiled: January 17, 2006Date of Patent: September 15, 2009Assignee: Cabochon Aesthetics, Inc.Inventors: Mark E. Deem, Hanson S. Gifford, III, Douglas Sutton
-
Publication number: 20090216117Abstract: A drug in the form of a solid preparation soluble or suspendable in water or an aqueous solution characterized by containing at least one biocompatible, gastric motility suppressing component such as triacetin, which is capable of transmitting ultrasonic wave to a target organ via the solution pooled in the body in a noninvasive examination (for example, an ultrasonic examination of an abdominal organ), identifying the area in which the solution exists, or clarifying the boundary of the solution and an organ in contact therewith, is employed as an auxiliary agent in the examination. In addition, triacetin can be extensively used as a gastric motility suppressor.Type: ApplicationFiled: April 17, 2006Publication date: August 27, 2009Applicants: SHINSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY, FUSHIMI PHARMACEUTICAL CO., LTD.Inventors: Shozo Koyama, Masaaki Tokuda, Yoshiyuki Hori, Kazumasa Ohsaka
-
Publication number: 20090202441Abstract: The present invention discloses methods and materials for killing and/or inhibiting the growth of a cancer cell via preferential entry of a cytotoxic compound. Preferential entry of the cytotoxic compound is accomplished by the use of protein transduction domains derived from cupredoxins, including the p18 and p28 truncations of azurin.Type: ApplicationFiled: December 18, 2008Publication date: August 13, 2009Inventors: Brad N. Taylor, Rajeshwari Mehta, Tohru Yamada, Craig Beattie, Tapas Das Gupta
-
Publication number: 20090196827Abstract: This invention provides an improvement to methods of drug loading of ultrasound contrast agents. Echogenic drug-loaded polymer microcapsules, nanocapsules, or mixtures thereof produced by the method of the invention wherein the echogenic drug-loaded polymer microcapsules, nanocapsules, or mixtures thereof contain at least 10% more of a drug as compared to (1) echogenic drug-loaded polymer microcapsules, nanocapsules, or mixtures thereof prepared by adding drug prior to emulsifying or (2) echogenic drug-loaded polymer microcapsules, nanocapsules, or mixtures thereof prepared by adding drug to lyophilized polymer microcapsules, nanocapsules, or mixtures thereof.Type: ApplicationFiled: May 21, 2007Publication date: August 6, 2009Applicant: Drexel UniversityInventors: Margaret A. Wheatley, Odelia Mualem Burstein, John R. Eisenbrey, Dalia El-Sherif
-
Publication number: 20090192505Abstract: The present invention relates to methods for treating tissue in the thoracic cavity of a subject by the application of a cryogen, or using the cryogen to create an isotherm in proximity to the tissue to be treated. A wide variety of conditions may be treated using the methods of the invention including asthma, neoplastic disease and a variety of conditions characterized by inflammation in lung and chest tissue.Type: ApplicationFiled: December 5, 2008Publication date: July 30, 2009Applicant: Reset Medical, Inc.Inventors: Timothy E. Askew, William S. Krimsky
-
Publication number: 20090180967Abstract: An ultrasonically active microparticle is taught that includes a porous interior particle having hydrophobic pores, a gas in the hydrophobic pores and a hydrophilic exterior shell surrounding the interior particle forming an ultrasonically active microparticle and allowing the microparticle to be suspended in an aqueous solution.Type: ApplicationFiled: January 15, 2009Publication date: July 16, 2009Inventors: Eugene Tu, Donald E. Ackley
-
Patent number: 7560110Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.Type: GrantFiled: August 8, 2005Date of Patent: July 14, 2009Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Hans J. Hansen, William J. McBride
-
Publication number: 20090169478Abstract: A non-invasive in vivo technique is disclosed, useful for example in detecting cancers and micrometastases. The technique may be used to selectively deliver drugs to target cells such as tumors, metastases, micrometastases, and individual malignant cells. Ligands with specificity for a target cell receptor, and optionally drug molecules as well, are covalently bound to magnetic nanoparticles, either directly or through a spacer molecule. The ligand precludes the need for a separate coating layer. For example, human breast cancer cells express receptors both for luteinizing hormone/chorionic gonadotropin (LH/CG), and for luteinizing hormone releasing hormone (LHRH). These cells can be specifically targeted by iron oxide nanoparticles covalently linked to LH/CG or LHRH. The nanoparticles are incorporated into the cancer cells through receptor-mediated endocytosis. The specific accumulation in targeted cancer cells enhances resolution for imaging, therapy, or both.Type: ApplicationFiled: August 4, 2006Publication date: July 2, 2009Applicant: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITYInventors: Carola Leuschner, Challa S.S.R. Kumar, William Hansel, Josef Hormes
-
Publication number: 20090162293Abstract: In some aspects, there are provided compositions and kits including annexin coupled to ultrasound contrast particles as well as methods utilizing these particles for diagnosis and treatment of pathological conditions characterized by apoptosis.Type: ApplicationFiled: August 21, 2008Publication date: June 25, 2009Applicant: Point Biomedical CorporationInventors: Jeffrey D. Gabe, Thomas B. Ottoboni
-
Publication number: 20090155170Abstract: The present invention provides methods and compositions for the treatment and diagnosis of diseases such as neoplastic diseases, neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and inflammatory diseases. The methods are based on the concept of pretargeting and include the administration of complexes comprising a recognizable compound A coupled to annexins, and the administration of complexes comprising of pharmaceutical or diagnostic compounds coupled to a compound B recognizing and binding to compound A to subjects. The compositions include annexins, annexin variants, that are not internalized by the target cells, derivatives thereof, and complexes thereof.Type: ApplicationFiled: December 12, 2006Publication date: June 18, 2009Inventors: Christiaan Peter Maria Reutelingsperger, Peter Moonen, Ad Vermaire
-
Publication number: 20090148385Abstract: A new type of contrast agent is described, which comprises matrix particles with a plurality of metal nanoparticles as well as the method of imaging therewith. A plurality of metal nanoparticles are encapsulated in a non-proteinaceous biocompatible or biodegradable matrix particle and/or attached to a non-proteinaceous biocompatible or biodegradable matrix particle, the matrix of the matrix particles being selected from the group consisting of a carbohydrate, a lipid, a synthetic polymer, an aqueous liquid, a surfactant and an organic liquid, or a mixture thereof. The matrix particles are biocompatible and/or biodegradable and can be coupled to targeting molecules for targeted visualization.Type: ApplicationFiled: November 15, 2005Publication date: June 11, 2009Applicant: KONINKLIJKE PHILIPS ELECTRONICS, N.V.Inventors: Nicolaas Petrus Willard, Ties Van Bommel
-
Patent number: 7534431Abstract: Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.Type: GrantFiled: February 2, 2004Date of Patent: May 19, 2009Assignee: Immunomedics, Inc.Inventors: William J. McBride, Hans J. Hansen, Chien-Hsing Ken Chang, David M. Goldenberg
-
Publication number: 20090117052Abstract: The present invention discloses an enhancement agent for high intensity focused ultrasound (HIFU) treatment, which is administered to a patient before HIFU treatment and can reduce the level of EEF at the target location to be treated with HIFU. EEF is presented by the expression: EEF=?Pt/V (unit: J/mm3), and refers to the HIFU energy needed to effectively treat a tumor per unit volume of the tumor, wherein, ?=0.7; P refers to the total acoustic power of HIFU source (unit: W); t refers to the total time of HIFU treatment (unit: s); V refers to the volume of HIFU-induced lesions (unit: mm3). If the amount of EEF at the target location before administration of the enhancement agent is defined as EEF(base) and the amount of EEF at the target location after administration of the enhancement agent is defined as EEF(measurement), the ratio between EEF(base) and EEF(measurement) is more than 1, preferably more than 2, and more preferably over 4.Type: ApplicationFiled: August 30, 2005Publication date: May 7, 2009Inventors: Zhibiao Wang, Faqi Li, Yanbing Xiao, Ziwen Xiao, Liping Liu, Zhilong Wang
-
Publication number: 20090104118Abstract: The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.Type: ApplicationFiled: December 19, 2008Publication date: April 23, 2009Inventors: Heike S. Radeke, David S. Casebier, Michael T. Azure, Douglas D. Dischino
-
Publication number: 20090098047Abstract: The present invention is directed to bioconjugates of complexes represented by the formula: wherein R, R?, R1, R?1, R2, R?2, R3, R?3, R4, R?4, R5, R?5, R6, R?6, R7, R?7, R8, R?8, R9, R?9, M, X, Y, Z and n are defined herein for use as contrast agents in diagnostic imaging.Type: ApplicationFiled: August 4, 2008Publication date: April 16, 2009Applicants: Inotek Pharmaceuticals, Kereos, Inc.Inventors: William L. Neumann, Dennis P. Riley, Randy H. Weiss, Susan L. Henke, Patrick J. Lennon, Karl W. Aston
-
Publication number: 20090092554Abstract: The present invention relates to the field of polymer chemistry and more particularly to encapsulated contrast agents and methods for using the same.Type: ApplicationFiled: April 30, 2008Publication date: April 9, 2009Applicant: Intezyne Technologies, Inc.Inventors: Habib Skaff, Kurt Breitenkamp, Kevin N. Sill
-
Publication number: 20090060847Abstract: A contrast agent for ultrasound examination of the prostate has contrast-intensifying particles on an exterior of which at least one binding molecule is present that specifically binds to CEACAM-1. In a method for ultrasound examination of the prostate, such a contrast agent is administered to the patient and a sonography of the prostate is subsequently implemented.Type: ApplicationFiled: September 3, 2008Publication date: March 5, 2009Inventors: Sueleyman Erguen, Jens Fehre, Ralf Nanke, Bernhard Singer, Derya Tilki
-
Publication number: 20090030308Abstract: Pain factors are labeled with targeted agents or markers delivered into the body. The labeled pain factors are imaged with appropriate imaging tools in a manner allowing selective identification and localization of areas of pain source or transmission. The labeled pain factors allow spatial differentiation in the imaging sufficient to specify the location of the pain so as to drive therapeutic decisions and techniques in order to treat the pain. Pain factors labeled and imaged in this manner may include one or more of nerve factors, blood vessel factors, cellular factors, and inflammation factors. Labeled markers may include for example radioactive materials (e.g. tritiated or iodinated molecules) or other materials such as metal (e.g. gold) nanoparticles. Intermediary binding materials may be used, such as for example bi-specific antibodies. Therapeutic components of the system and method include for example localized energy delivery or ablation treatments, or local drug or other chemical delivery.Type: ApplicationFiled: March 21, 2008Publication date: January 29, 2009Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: David S. Bradford, Jeffrey C. Lotz
-
Publication number: 20090028797Abstract: The present invention provides a novel method of manufacturing nanosized polymeric echogenic contrast agents. The method of the present invention comprises a modified salting out process which results on nanosized polymeric capsules encapsulating an aqueous core that is subsequently evacuated. The compositions of the present invention can be used as contrast agents as well as to deliver therapeutic agents to specific targets.Type: ApplicationFiled: June 13, 2008Publication date: January 29, 2009Inventors: Margaret A. Wheatley, John Lewandowski
-
Patent number: 7468177Abstract: Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume in vivo.Type: GrantFiled: July 16, 2007Date of Patent: December 23, 2008Assignee: Mallinckrodt Inc.Inventors: Samuel Achilefu, Raghavan Rajagopalan, Richard B. Dorshow, Joseph E. Bugaj, Muthunadar P. Periasamy
-
Publication number: 20080311046Abstract: An ultrasound contrast agent composed of at least one kind of low-boiling water-insoluble substance (with a boiling point lower than 37° C.) and at least one kind of high-boiling water-insoluble substance (with a boiling point higher than 37° C.). The former vaporizes to absorb ultrasonic energy upon application of ultrasound, thereby causing the latter to vaporize secondarily, with the resulting bubbles producing an echo image. It is less liable to bumping and hence safe.Type: ApplicationFiled: August 4, 2005Publication date: December 18, 2008Inventors: Kenichi Kawabata, Nami Sugita, Shin-ichiro Umemura
-
Publication number: 20080305046Abstract: This invention relates generally to minimally-invasive, in vivo methods of detecting one or more ligands on an intraluminal surface of a blood vessel using microparticles coated with one or more ligand binding partners. More particularly, in certain embodiments, the invention relates to minimally-invasive, in vivo methods of detecting endothelial and leukocyte antigens that are predictive of diabetic retinopathy (DR) and/or other conditions using protein-conjugated microparticles detectable by a non-invasive detection system, for example, a scanning laser opthalmoscope. In other embodiments, the invention relates to targeted delivery of drugs or other substances to specific regions of an intraluminal surface of a blood vessel using drug-containing microparticles coated with one or more ligand binding partners.Type: ApplicationFiled: January 7, 2008Publication date: December 11, 2008Inventor: Ali Hafezi-Moghadam
-
Publication number: 20080286205Abstract: A method for treating prostate related diseases in a subject, the method comprising i) optionally administering to subject an initial boost dose of one or more active substances and/or prodrugs, and ii) administering locally into the prostate a controlled release pharmaceutical composition comprising one or more active substances in a biodegradable ceramic carrier. The biodegradable hydrating ceramic may be selected from the group consisting of non-hydrated or hydrated calcium sulphate, calcium phosphate, calcium carbonate, calcium fluoride, calcium silicate, magnesium sulphate, magnesium phosphate, magnesium carbonate, magnesium fluoride, magnesium silicate, barium sulphate, barium phosphate, barium carbonate, barium fluoride, barium silicate, or mixtures thereof. In a specific embodiment, the biodegradable hydrating ceramic is non-hydrated or hydrated calcium sulphate.Type: ApplicationFiled: March 31, 2006Publication date: November 20, 2008Applicant: Lidds AbInventors: Hans Lennernas, Bo Lennernas, Jonas Hugosson, Niklas Axen
-
Publication number: 20080286206Abstract: The present invention relates to an image enhancing composition for the enhancement of contrast in a body cavity, wherein the viscosity of the composition is between 2000 and 4000 mPa·sec. It also relates to a method for enhancing contrast of an image of a body cavity, which method involves introducing one single small aliquot of an image enhancing composition into the body cavity. In another aspect, the present invention provides a high contrast image of a body cavity obtained by the method of the invention, in particular a 3-dimensional high contrast image.Type: ApplicationFiled: July 14, 2005Publication date: November 20, 2008Applicant: Gynaecologiq B.V.Inventors: Mark Hans Emanuel, Niek Exalto
-
Patent number: 7452551Abstract: Novel targeted compositions which may be used for diagnostic and therapeutic use. The compositions may comprise lipid, protein or polymer gas-filled vesicles which further comprise novel compounds of the general formula L-P-T, wherein L comprises a hydrophobic compound, P comprises a hydrophilic polymer, and T comprises a targeting ligand which targets tissues, cells or receptors, including myocardial cells, endothelial cells, epithelial cells, tumor cells and the glycoprotein GPIIbIIIa receptor. The compositions can be used in conjunction with diagnostic imaging, such as ultrasound, as well as therapeutic applications, such as therapeutic ultrasound.Type: GrantFiled: October 30, 2000Date of Patent: November 18, 2008Assignee: ImaRx Therapeutics, Inc.Inventors: Evan C. Unger, Terry O. Matsunaga, Patricia A. Schumann
-
Publication number: 20080260634Abstract: Methods of imaging tumors are disclosed. The methods utilize an endothelin ETB receptor agonist or an endothelin ETA receptor antagonist, in combination with an imaging agent, to detect a tumor in mammals, including humans.Type: ApplicationFiled: November 21, 2005Publication date: October 23, 2008Inventors: Anil Gulati, Kartike Gulati
-
Publication number: 20080260648Abstract: A pharmaceutical preparation containing magnetic vesicular particles is disclosed, wherein the magnetic vesicular particles each include magnetic microparticles within a lipid membrane, an organic compound having at least two groups selected from the group consisting of a hydroxyl group, a carboxyl group, a carbamoyl group, an amino group, a mercapto group, a sulfo group, a dithio group, a thiocarboxyl group and a dithiocarboxyl group is bonded to the magnetic microparticle, and the magnetic vesicular particles satisfy the following equation: 0.05?R/(r×100)?1.5 wherein R represents an average grain size of the magnetic vesicular particles and r represents an average particle size of magnetic microparticles included in the magnetic vesicular particles.Type: ApplicationFiled: October 26, 2007Publication date: October 23, 2008Applicant: KONICA MINOLTA MEDICAL & GRAPHIC, INC.Inventor: Toshihisa Takeyama
-
Patent number: 7438894Abstract: Highly hydrophilic indole and benzoindole derivatives that absorb and fluoresce in the visible region of light are disclosed. These compounds are useful for physiological and organ function monitoring. Particularly, the molecules of the invention are useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume in vivo.Type: GrantFiled: October 7, 2003Date of Patent: October 21, 2008Assignee: Mallinckrodt, Inc.Inventors: Samuel Achilefu, Raghavan Rajagopalan, Richard B. Dorshow, Joseph E. Bugaj, Muthunadar P. Periasamy
-
Publication number: 20080253960Abstract: The present invention provides a non-naturally occurring lipoprotein nanoplatform (“LBNP”) comprising at least one cell surface receptor ligand; at least one lipoprotein; and at least one diagnostic agent and/or at least one therapeutic agent. In embodiments of the present invention, the cell surface receptor ligand is not a low-density lipoprotein receptor ligand and the cell surface receptor ligand is covalently bonded to the apoprotein. The present invention also provides pharmaceutical formulations comprising LBNPs and methods of making the LBNPs.Type: ApplicationFiled: April 1, 2005Publication date: October 16, 2008Applicant: The Trustees of the University of Pennsylvania Center for Technology TransferInventors: Gang Zheng, Jerry D. Glickson
-
Publication number: 20080247943Abstract: Emulsions comprising nanoparticles formed from high boiling perfluorochemical substances, said particles coated with a lipid/surfactant coating are made target-specific by directly coupling said nanoparticles to a targeting ligand. The nanoparticle may further include biologically active agents, radionuclides, and/or other imaging agents, and are used to image and/or lyse blood clots in human subjects.Type: ApplicationFiled: August 20, 2003Publication date: October 9, 2008Inventors: Gregory Lanza, Samuel A. Wickline
-
Publication number: 20080247957Abstract: The present invention comprises minimally invasive methods useful in the treatment of liver cancer. The method of the present invention comprises administering to an individual with liver cancer an injectable, echogenic nanocapsule and/or microcapsule wherein the nanocapsule and/or microcapsule comprises a therapeutic agent, a targeting moiety, or a combination thereof. The method of the present invention further comprises monitoring the distribution of the nanocapsule and/or microcapsule using ultrasound. The method of the invention delivers a therapeutic agent to a liver cancer cell either by biodegradation of a nanocapsule and/or microcapsule comprising a therapeutic agent, or by altering the biodegradation of a nanocapsule and/or microcapsule using ultrasound.Type: ApplicationFiled: February 15, 2008Publication date: October 9, 2008Inventor: Margaret A. Wheatley
-
Publication number: 20080226560Abstract: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The cargo compound may be a nucleic acid and specifically a DNA, RNA or anti-sense. The invention further discloses methods for treating cancer and diagnosing cancer.Type: ApplicationFiled: February 8, 2008Publication date: September 18, 2008Inventors: Tapas DAS GUPTA, Ananda Chakrabarty, Craig Beattie, Tohru Yamada
-
Patent number: 7422733Abstract: Disclosed herein is a class of linkable tetrasaccharide compounds that includes the amino phenyl glycoside of sialyl Lewis X (SLeX) and related analogs. These compounds have conjugatable nucleophilic groups, making them useful in preparing multimeric SLeX compositions. In particular, the disclosed SLeX compounds can be used to prepare selectin binding ligand conjugates by linking them to a reporter moiety, such as a contrast agent, a radiodiagnostic agent, or a cytotoxic or chemotherapeutic agent. The SLeX compounds and conjugates of the invention exhibit binding to selectin that is similar to native Sialyl Lex, and are, therefore, useful for diagnosing and treating selectin-mediated disorders and related conditions.Type: GrantFiled: November 29, 2001Date of Patent: September 9, 2008Assignee: Bracco International B.V.Inventors: Ramachandran Ranganathan, Kondareddiar Ramalingam, Radhakrishua Pillai, Edmund E. Marinelli, Rolf E. Swenson